{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:42Z","timestamp":1788844242636,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Psoriasis and IgA nephropathy are immune-mediated disorders that may coexist, but the clinical meaning of this association remains uncertain. We report a 45-year-old man with psoriasis and progressive kidney dysfunction whose biopsy-proven IgA nephropathy presented with severe impairment of kidney function, heavy proteinuria, and mixed active and chronic histologic injury. At reassessment, serum creatinine was 463 \u03bcmol\/L, estimated glomerular filtration rate was 12.1 mL\/min\/1.73 m\u00b2, and pretreatment 24-hour urinary protein excretion ranged from 2.90 to 4.70\u00a0g. Kidney biopsy showed proliferative sclerosing IgA nephropathy, Oxford classification M1E1S1T2C0, with ischemic glomerular injury, microangiopathy, tubular atrophy, and interstitial fibrosis. Targeted-release budesonide and deucravacitinib were started together. Proteinuria fell to 0.62\u00a0g, serum creatinine decreased to 323 \u03bcmol\/L, and a modest improvement in cutaneous disease activity was observed, with PASI decreasing from 2.4 to 1.6. After patient-initiated discontinuation of deucravacitinib, proteinuria increased and later declined after reintroduction. Following completion of the planned budesonide course, proteinuria continued to fall during deucravacitinib monotherapy, while kidney function deteriorated. This case is best interpreted as a clinicopathologic observation rather than proof of drug efficacy. Biopsy-defined activity and chronicity helped explain the discordant changes in proteinuria and kidney function, while the longitudinal course generated a testable but unproven hypothesis of a possible inflammatory connection between psoriasis and IgA nephropathy.<\/jats:p>","DOI":"10.3389\/fneph.2026.1932773","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:57Z","timestamp":1788841617000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Advanced IgA nephropathy with psoriasis and a complex clinicopathologic course"],"prefix":"10.3389","volume":"6","author":[{"given":"Lerui","family":"Wang","sequence":"first","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"Iga nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.003","article-title":"Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14961","article-title":"The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study","volume":"176","author":"Grewal","year":"2017","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10238-025-01750-8","article-title":"Clinicopathological features and renal outcomes in patients with IgA nephropathy secondary to psoriasis","volume":"25","author":"He","year":"2025","journal-title":"Clin Exp Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000013388","article-title":"Iga nephropathy in psoriasis","volume":"18","author":"Ahuja","year":"1998","journal-title":"Am J Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/joneph\/19.3.382","article-title":"Iga nephropathy associated with psoriasis vulgaris: a contribution to the entity of psoriatic nephropathy","volume":"19","author":"Zadrazil","year":"2006","journal-title":"J Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000015433","article-title":"Iga nephropathy associated with erythrodermic psoriasis: a case report","volume":"98","author":"Zhang","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242627","article-title":"Severe psoriasis presenting with rapidly progressive (crescentic) IgA-predominant glomerulonephritis","volume":"14","author":"Garces","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-019-00393-5","article-title":"A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab","volume":"8","author":"Ochi","year":"2019","journal-title":"CEN Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16903","article-title":"A case of psoriasis with IgA nephropathy successfully treated with secukinumab","volume":"63","author":"Kulakl\u0131","year":"2024","journal-title":"Int J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multicenter, double-blind, randomized, placebo-controlled NefIgArd trial evaluating targeted-release budesonide for primary IgA nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.007","article-title":"A targeted-release formulation of budesonide for the treatment of IgA nephropathy patients with severe renal impairment","volume":"10","author":"Ouyang","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20553","article-title":"Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2 and long-term extension trials","volume":"39","author":"Armstrong","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms24043391","article-title":"Tyk2 targeting in immune-mediated inflammatory diseases","volume":"24","author":"Rusi\u00f1ol","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s462797","article-title":"The role of interleukin 23\/17 axis in psoriasis management: a comprehensive review of clinical trials","volume":"17","author":"Potestio","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2024.2321901","article-title":"Th17 cells: a new target in kidney disease research","volume":"43","author":"Zhang","year":"2024","journal-title":"Int Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.12.023","article-title":"Elevated urinary IL-6 predicts the progression of IgA nephropathy","volume":"8","author":"Zhao","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1932773\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:27:00Z","timestamp":1788841620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1932773\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":18,"alternative-id":["10.3389\/fneph.2026.1932773"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1932773","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1932773"}}